Genmab — Januar 2021
-
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis -
Nice!
-
Troldene inspirerer de mange kommaer - fedt at vi kan holde det på de store linier
-
Gen (dk) er oppe med små 10pct ytd, mens NBI er oppe med 7pct ytd - ser vi GEN følge markedet eller er der noget ekstra krudt i GEN?
-
4000 pts årligt i US https://www.cancer.net/cancer-types/amyloidosis/statistics
-
32.000 pts årligt med multiple
myeloma https://www.cancer.net/cancer-types/multiple-myeloma/statistics -
Men hvor meget er dara egentlig i GEN længere?
-
Hexa-cd38 vil alligevel overtage daras marked
-
For mig har dara altid været en poison pill ifht opkøb - men nu da porteføljen er bredere og de kommercielle muligheder er større for BP, så kan GEN komme på menukortet hos de store drenge igen
-
Så kan man jo altid sælge dara fra til JJ
-
https://finance.yahoo.com/news/bristol-myers-freeing-cash-additional-195202691.html De købte Genmabs moderselskab. Nogle gange er datteren bedre
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind